Innophos’ A-Tab® MD Proven to Improve Chewable Tablets

CRANBURY, NJ — Innophos, a leader in specialty ingredient solutions, highlights new application data demonstrating that A-Tab® MD, a multifunctional co-processed excipient, improves chewable tablet formulations by enabling higher active loading while maintaining tablet integrity.

Formulators of chewable tablets often face limitations when increasing active content, as higher loading levels can negatively impact compressibility, friability, and overall tablet performance. A-Tab® MD addresses these challenges by supporting tablet structure at elevated active concentrations.

In technical evaluations, A-Tab® MD enabled active loading levels of up to 40%, compared to approximately 20% with leading commercial chewable formats. This performance was supported by improved friability and reduced reliance on additional excipients, helping streamline formulations and improve efficiency.

By enabling higher active content within a consistent tablet size, A-Tab® MD allows manufacturers to deliver a full serving in a single dose while maintaining product quality and a positive consumer experience.

A-Tab® MD is part of Innophos’ broader portfolio of science-backed solutions designed to address evolving challenges in pharmaceutical and nutraceutical applications.

Connect with Innophos to explore how A-Tab® MD can support your next chewable tablet formulation.